Rosetta Genomics Ltd
OTC:ROSGQ
Rosetta Genomics Ltd
Revenue
Rosetta Genomics Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rosetta Genomics Ltd
OTC:ROSGQ
|
Revenue
$9.2m
|
CAGR 3-Years
184%
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Revenue
$11m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Revenue
$142.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Revenue
$82.7m
|
CAGR 3-Years
91%
|
CAGR 5-Years
136%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Revenue
₪0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rosetta Genomics Ltd's Revenue?
Revenue
9.2m
USD
Based on the financial report for Dec 31, 2016, Rosetta Genomics Ltd's Revenue amounts to 9.2m USD.
What is Rosetta Genomics Ltd's Revenue growth rate?
Revenue CAGR 5Y
146%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Rosetta Genomics Ltd have been 184% over the past three years , 146% over the past five years .